Stock Track | Janux Therapeutics Soars 5.05% Following Bank of America's Buy Rating Reiteration

Stock Track

Aug 13, 2025

Shares of Janux Therapeutics, Inc. (JANX) are soaring 5.05% in Wednesday's pre-market trading session, following a bullish analyst report from Bank of America Securities. The surge comes as investors react positively to the reiterated Buy rating on the biopharmaceutical company's stock.

Alec Stranahan, an analyst at Bank of America Securities, maintained a Buy rating on Janux Therapeutics in a report released early Wednesday. While the specific price target was not disclosed in the available information, the analyst's continued confidence in the company appears to be driving investor enthusiasm.

Janux Therapeutics, known for its innovative approach to cancer therapeutics, has been gaining attention in the biotech sector. The company's strong clinical profile and strategic trial designs likely contribute to the positive outlook from analysts. As the biopharmaceutical industry continues to evolve, Janux's potential in developing novel cancer treatments seems to be resonating with both analysts and investors alike.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1133429894"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133429894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133429894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133429894","market":"hk","top_or_hot":-1,"title":"Stock Track | Janux Therapeutics Soars 5.05% Following Bank of America's Buy Rating Reiteration","media":"Stock Track","content":"<p>Shares of Janux Therapeutics, Inc. (JANX) are soaring 5.05% in Wednesday's pre-market trading session, following a bullish analyst report from Bank of America Securities. The surge comes as investors react positively to the reiterated Buy rating on the biopharmaceutical company's stock.</p>\n\n<p>Alec Stranahan, an analyst at Bank of America Securities, maintained a Buy rating on Janux Therapeutics in a report released early Wednesday. While the specific price target was not disclosed in the available information, the analyst's continued confidence in the company appears to be driving investor enthusiasm.</p>\n\n<p>Janux Therapeutics, known for its innovative approach to cancer therapeutics, has been gaining attention in the biotech sector. The company's strong clinical profile and strategic trial designs likely contribute to the positive outlook from analysts. As the biopharmaceutical industry continues to evolve, Janux's potential in developing novel cancer treatments seems to be resonating with both analysts and investors alike.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Janux Therapeutics Soars 5.05% Following Bank of America's Buy Rating Reiteration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Janux Therapeutics Soars 5.05% Following Bank of America's Buy Rating Reiteration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-13 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Janux Therapeutics, Inc. (JANX) are soaring 5.05% in Wednesday's pre-market trading session, following a bullish analyst report from Bank of America Securities. The surge comes as investors react positively to the reiterated Buy rating on the biopharmaceutical company's stock.</p>\n\n<p>Alec Stranahan, an analyst at Bank of America Securities, maintained a Buy rating on Janux Therapeutics in a report released early Wednesday. While the specific price target was not disclosed in the available information, the analyst's continued confidence in the company appears to be driving investor enthusiasm.</p>\n\n<p>Janux Therapeutics, known for its innovative approach to cancer therapeutics, has been gaining attention in the biotech sector. The company's strong clinical profile and strategic trial designs likely contribute to the positive outlook from analysts. As the biopharmaceutical industry continues to evolve, Janux's potential in developing novel cancer treatments seems to be resonating with both analysts and investors alike.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JANX","symbol_name":"Janux Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1133429894","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133429894","pubTimestamp":1755094946,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Janux Therapeutics, Inc. (JANX) are soaring 5.05% in Wednesday's pre-market trading session, following a bullish analyst report from Bank of America Securities. The surge comes as investors...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JANX":"Janux Therapeutics, Inc."},"translate_title":"个股追踪|美银重申买入评级后Janux Therapeutics大涨5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JANX":1},"content_text":"Shares of Janux Therapeutics, Inc. (JANX) are soaring 5.05% in Wednesday's pre-market trading session, following a bullish analyst report from Bank of America Securities. The surge comes as investors react positively to the reiterated Buy rating on the biopharmaceutical company's stock.\nAlec Stranahan, an analyst at Bank of America Securities, maintained a Buy rating on Janux Therapeutics in a report released early Wednesday. While the specific price target was not disclosed in the available information, the analyst's continued confidence in the company appears to be driving investor enthusiasm.\nJanux Therapeutics, known for its innovative approach to cancer therapeutics, has been gaining attention in the biotech sector. The company's strong clinical profile and strategic trial designs likely contribute to the positive outlook from analysts. As the biopharmaceutical industry continues to evolve, Janux's potential in developing novel cancer treatments seems to be resonating with both analysts and investors alike.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}